It would be medically useful to determine whether downregulating the TL1A/DR3 pathway can prevent the progression of IBD-associated fibrosis since there is currently no effective medical therapy to treat established fibrostenotic disease in IBD patients. The gene discussed is TNFRSF25; the disease is inflammatory bowel disease.